Equities

Probi AB

Probi AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)211.00
  • Today's Change6.00 / 2.93%
  • Shares traded814.00
  • 1 Year change+18.54%
  • Beta0.6485
Data delayed at least 15 minutes, as of Mar 28 2024 10:55 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Probi AB is a Sweden-based company engaged in the probiotics research and development. The Company’s activities are divided into two business areas: Functional Foods, which focuses on the probiotics application in food in partnership with food companies; and Consumer Healthcares, which develops, commercializes and sells Probi probiotics in collaboration with a range of entities, such as pharmaceutical companies and firms related to the production of probiotics and self-care goods. Its brands portfolio comprises two trademarks: Probi Digestis and Probi Defendum. The Company's partners include Danone, Skanemejerier, NextFoods, Sanum Polska, Heinz, Kraft Foods, and Institut Rosell, among others. The Company is a parent of Probi Food AB and Probi Feed AB.

  • Revenue in SEK (TTM)627.69m
  • Net income in SEK16.82m
  • Incorporated--
  • Employees168.00
  • Location
    Probi ABIdeongatan 1ALUND 223 70SwedenSWE
  • Phone+46 462868920
  • Fax+46 462868928
  • Websitehttps://probi.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Photocure ASA492.84m262.83k1.47bn106.007,660.173.0953.352.980.00720.007218.5817.790.70010.82039.37--0.0375-3.090.0429-3.5694.7893.640.0535-5.194.32--0.00--27.3522.50100.37--49.83--
Arcticzymes Technologies ASA117.08m18.43m1.47bn61.0079.294.8459.4712.550.37020.37022.356.070.36180.59412.43--5.6915.526.1217.1695.0296.6915.7433.1012.43--0.0392---13.1612.24-43.02--47.93--
Hansa Biopharma AB134.09m-831.72m1.55bn168.00------11.53-15.84-15.842.55-3.190.099150.802.22798,178.60-61.48-47.96-78.47-56.1252.9164.18-620.25-835.042.66-18.631.24---13.22109.06-36.09---35.24--
Devyser Diagnostics AB-100.00bn-100.00bn1.64bn118.00--4.27----------23.65-----------8.97---10.15--80.14---23.915.11--0.1626--33.7128.59-16.64--44.59--
Vicore Pharma Holding AB0.00-310.94m1.68bn26.00--3.68-----3.24-3.240.004.080.00-------74.54-58.68-83.09-65.58------------0.00-------7.81------
Egetis Therapeutics AB (publ)57.50m-326.90m1.93bn25.00--3.54--33.58-1.28-1.280.2241.860.08716.923.59---49.44-33.02-55.92-36.4680.87---568.00-357.723.32--0.1688--154.8715.35-68.68------
Genovis AB158.23m61.50m2.17bn37.0035.2411.3630.4213.690.93940.93942.422.910.7203----4,276,514.0027.9918.5630.7421.4572.2065.5138.8723.88--------54.5435.56449.56------
Nanoform Finland Oyj29.48m-238.47m2.28bn165.00--2.96--77.36-0.2674-0.26740.03310.85350.0287138.934.1115,548.42-23.22-27.13-25.12-29.48-507.09-604.26-809.08-1,023.708.16--0.0964---26.4161.315.98--53.92--
Probi AB627.69m16.82m2.34bn168.00138.881.7120.673.721.481.4855.09120.160.41023.507.42--1.104.641.164.9835.0842.042.689.835.44--0.037821.421.520.7684-58.60-26.0931.01--
Data as of Mar 28 2024. Currency figures normalised to Probi AB's reporting currency: Swedish Krona SEK

Institutional shareholders

14.54%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 30 Jun 20231.06m9.28%
Swedbank Robur Fonder ABas of 31 Dec 2022206.74k1.81%
SEB Investment Management AB (Denmark)as of 28 Feb 202297.02k0.85%
Handelsbanken Fonder ABas of 29 Feb 202469.42k0.61%
Nordea Investment Management AB (Finland)as of 31 Aug 202367.24k0.59%
Deka Investment GmbHas of 30 Sep 202360.98k0.54%
SEB Investment Management ABas of 29 Feb 202459.10k0.52%
Skandia Investment Management ABas of 31 Jan 202418.29k0.16%
MFS International (UK) Ltd.as of 31 Jan 202417.07k0.15%
Storebrand Asset Management ASas of 31 Jan 20244.20k0.04%
More ▼
Data from 30 Nov 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.